IngredientsAlpha-glycosyl isoquercitrin (AGIQ), also known as enzymatically modified isoquercitrin (EMIQ), is formally described as α-oligoglucosyl quercetin 3-O-glucoside. It is produced through the enzymatic conversion of rutin (RT) into a mixture of isoquercitrin (IQ) and its α-glucosyl derivatives bearing 1–10 α-glucose moieties connected linearly via a 1→4 linkage (designated IQG1 through IQG10).
The mean content of IQ through IQG7 in the commercial mixture is over 94%, while free quercetin aglycone is present at less than 1%. The average molecular weight of EMIQ is approximately 800 Daltons.
The compound belongs to the flavonol subclass of flavonoids. Its immediate precursor, isoquercitrin, is formally quercetin-3-O-β-D-glucopyranoside, itself one of the major glycosidic forms of the natural flavonol quercetin (3,5,7,3′,4′-pentahydroxyflavone).
Common synonyms and designations used in the scientific literature include:
EMIQ has high resistance to oxidative degradation and higher thermal stability than quercetin. It is an enzymatically transformed mixture of isoquercitrin α-oligoglucosides with improved bioavailability compared to natural dietary flavonoids such as quercitrin, isoquercitrin, or rutin, and is additionally characterized by enhanced water solubility, stability, and thermal resistance.
EMIQ is derived from rutin, which is extracted from the flowers and buds of the Japanese pagoda tree (Sophora japonica L.). Rutin required for EMIQ production is also isolated from the entire plant of Vigna angularis (Willd.) (adzuki bean) and related plant species.
Rutin itself is a flavonoid glycoside ubiquitously present in a variety of fruits and vegetables, including onions and buckwheat. Rutin is found in the highest amounts in buckwheat, tomato, apricot, rhubarb, tea, celery, spinach, Brussels sprouts, and lemon, and the rutin used in dietary supplements is typically derived from Dimorphandra spp. (Brazil) and Sophora japonica (Asia).
The flavonoid isoquercitrin (quercetin-3-O-β-D-glucopyranoside) is commonly found in medicinal herbs, fruits, vegetables, and plant-derived foods and beverages. The flavonols rutin, quercetin, and isoquercetin are found not only in foods such as apple and onion, but in many medicinal plants, including Aesculus hippocastanum (horse chestnut), Ruscus aculeatus (butcher's broom), Ginkgo biloba (ginkgo), and Hypericum perforatum (St. John's wort).
It is important to note that AGIQ/EMIQ itself does not occur in nature. Alpha-glycosyl isoquercitrin is a modern, bio-enhanced derivative developed through advancements in flavonoid chemistry and enzymology in the late 20th and early 21st centuries; it does not appear in any traditional medical systems or historical pharmacopeias in its current form.
While AGIQ itself has no traditional history of use, its precursor molecules — rutin, quercetin, and the plant Sophora japonica — have significant histories within traditional medicine systems.
Rutin and quercetin are known as "vitamin P" and play various roles in cardiovascular and metabolic health. The most commonly accepted traditional medical use of flavonols is in the maintenance of capillary integrity, for which the flavonols were applied topically, ingested, or taken by both routes concurrently. Flavonols have also demonstrated neuroprotective, cardioprotective, chemopreventive, antioxidant, anti-inflammatory, and anti-allergic activity in numerous preclinical studies.
Quercetin and rutin inhibit the generation of inflammatory mediators (leukotriene LTB4 and prostaglandin E2) in human neutrophils, suggesting potential application in the treatment of inflammatory conditions associated with excessive leukotriene production, such as rheumatoid arthritis and inflammatory bowel disease.
The flowers and buds of Sophora japonica (syn. Styphnolobium japonicum) have been used in Traditional Chinese Medicine (TCM) for centuries as a hemostatic agent and to strengthen capillary walls, a use attributed in part to its high rutin content. These traditional applications provided the ethnobotanical rationale for subsequent scientific investigation of rutin and its derivatives, ultimately leading to the development of AGIQ.
EMIQ is produced from rutin via enzymatic hydrolysis, which removes the rhamnosyl group to yield isoquercitrin, followed by treatment of the product with glycosyltransferase in the presence of dextrin to add glucose residues. More specifically, large volumes of isoquercitrin can be manufactured via enzymatic hydrolysis of rutin and then transglycosylated using dextrin and cyclodextrin glucanotransferase (CGTase) to produce alpha-glycosyl isoquercitrin (AGIQ).
EMIQ was first developed in 1987 and approved by the Japanese Ministry of Health and Welfare for use as a food additive in 1996. Its monograph with quality requirements is contained in the latest edition of Japan's Specifications and Standards for Food Additives.
The primary commercial producer of EMIQ is San-Ei Gen F.F.I., Inc., located in Toyonaka, Japan.
In Japan, EMIQ has been approved as a nutraceutical and food additive in various beverages and foods, and the U.S. Food and Drug Administration (FDA) concluded that EMIQ is generally regarded as safe (GRAS Notice 220) for use as an antioxidant. Alpha-glycosyl isoquercitrin (AGIQ) is marketed in Japan as a food additive and is generally recognized as safe (GRAS) by the expert panel of the Flavor and Extract Manufacturers Association (FEMA) in 2005 and the U.S. Food and Drug Administration (FDA) in 2007.
In commerce, AGIQ/EMIQ is available in the following forms:
EMIQ is used as a food additive for protection of flavors, colors, and freshness in multiple food categories including fruit and vegetable juices, jams, jellies, and milk products.
EMIQ is produced as a mixture of IQ and its α-glucosyl derivatives with 1–10 α-glucose moieties connected linearly via 1→4 linkage (IQG1-IQG10). The mean content of IQ through IQG7 in the mixture is over 94%; free quercetin aglycone is present at less than 1%.
HPLC analyses of EMIQ showed it to contain 1–12 glucosides and 10.7% pentahydroxyflavonoids, indicating strong antioxidant properties.
Upon ingestion, the oligoglucosyl chains are removed by digestive enzymes, liberating quercetin aglycone for absorption. After ingestion in humans, AGIQ is deglycosylated in part by salivary amylase, absorbed to some extent in the small intestine, and metabolized in the large intestine by anaerobic enterobacteria to form quercetin, which is absorbed and quickly glucuronidated. The aromatic rings of quercetin can also be metabolized by other large intestinal bacteria to phenyl and hydroxyphenylacetic acids and short-chain fatty acids that are then absorbed.
Low oral bioavailability of quercetin due to its insolubility in water has limited its use as a food additive or dietary supplement. Since water solubility is enhanced by glycosyl conjugation, the addition of alpha-glucose chains substantially increases intestinal absorption.
The oligoglycoside moiety added to quercetin via enzymatic modification increases the hydrophilic properties and enhances the bioavailability of the obtained substance. Such a product dissolves easily in the gastrointestinal fluids and is readily digested at the intestinal mucosa membranes to yield quercetin ready for absorption.
EMIQ appears to be effectively transported to intestinal epithelial cells through the "unstirred" water layer before being hydrolyzed by mucosal maltase-glucoamylase and lactase phlorizin hydrolase (LPH), and efficiently incorporated into cells as the aglycone form.
Animal research showed that the true bioavailability (AUCoral/AUCintravenous, expressed as a percentage) of EMIQ after oral administration, assessed as total plasma quercetin levels, was 35% — approximately 17-, 3-, and 44-times higher than that of quercetin aglycone (2%), isoquercitrin (12%), and rutin (0.8%), respectively.
In the only study with human participants, quercetin 3-glucuronide, quercetin 3′-sulphate, and isorhamnetin 3-glucuronide were reported as the main metabolites. Substantial variation was observed between individual subjects in terms of quantitative ratios between different metabolites; however, in general, the metabolite profile of EMIQ was similar to that after isoquercitrin administration. The maximal plasma concentration of the metabolites was achieved after 1.5–2 hours and was approximately three-times higher than that obtained for isoquercitrin.
Scavenging of oxidative stress-inducing free radicals by the phenolic hydroxyl groups of quercetin and its glycosides enables these compounds to act as powerful antioxidants. Quercetin's catechol moiety on the B-ring and the 3-OH group on ring C are widely accepted as the main structural features responsible for its radical-scavenging capacity.
Quercetin has been shown to inhibit cytokine and inducible nitric oxide synthase expression through inhibition of the NF-κB pathway, which accounts for its anti-inflammatory capacity.
In vitro, quercetin and related flavonols exert endothelium-independent vasodilator effects, protective effects on nitric oxide and endothelial function under conditions of oxidative stress, platelet anti-aggregant effects, inhibition of LDL oxidation, and reduction of adhesion molecules and other inflammatory markers.
In animal models, the anti-obesity effect of EMIQ is associated with dose-dependent upregulation of genes linked to mitochondrial oxidative metabolism and PKA signaling (related to lipolysis), elevated cAMP levels, and AMPK activation in adipose tissue, along with increased excretion of fecal lipids. EMIQ treatment enhanced energy metabolism mainly by phosphorylating 5′ adenosine monophosphate-activated protein kinase (AMPK) in white adipose tissue.
In experimental carcinogenesis models, EMIQ administration reduced the transcription of the Cyp2b2 gene, which is a phase I drug-metabolizing enzyme involved in the generation of oxidative stress that may be responsible for the formation of preneoplastic lesions.
EMIQ is an isoquercitrin derivative obtained from rutin via enzymatic transformations that greatly enhance its bioavailability, and due to advantageous reports on its safety and bioactivity, EMIQ is currently gaining importance as a food additive and a constituent of dietary supplements.
In a randomized, placebo-controlled, double-blind trial in athletes, one group received 20 g of supplemental whey protein powder with 42 mg EMIQ, and the other consumed whey protein only (six times a week immediately after practice for 4 months). The results suggested that EMIQ supplementation may optimize the effect of exercise and increase muscle hypertrophy. The effects were evidenced by a significant increase in lower limb fat-free mass and muscle mass, exceeding the impact of training alone. The authors suggested that the results may be related to the antioxidant properties of EMIQ, as improvement in antioxidant status was observed, though other mechanisms are possible and require further investigation.
Evidence strength: Preliminary. One small randomized controlled trial (RCT) in a specific population (male athletes); antioxidant biomarker improvements noted but the underlying mechanism and generalizability remain unconfirmed.
A notable human intervention study published in the British Journal of Nutrition examined the acute effects of EMIQ on endothelial function. After adjustment for pre-treatment measurements and treatment order, EMIQ® treatment resulted in a significantly higher flow-mediated dilatation (FMD) response compared to placebo (0.60%, 95% CI: 0.03, 1.17; p=0.04). Plasma concentrations of quercetin metabolites were significantly higher (p<0.001) after EMIQ® treatment compared to placebo. No changes in blood pressure, arterial stiffness, cognitive function, or biochemical parameters were observed. The authors concluded that in this human intervention study, the acute administration of EMIQ® significantly increased circulating quercetin metabolites and improved endothelial function, but further clinical trials are required to assess whether health benefits are associated with long-term EMIQ® consumption.
In a human study with 100 mg quercetin equivalent intake, EMIQ produced a higher plasma concentration of quercetin conjugates 90 minutes after ingestion, compared with intact isoquercitrin (Q3G).
In animal models of atherosclerosis, supplementing the diet of apoE-deficient mice with EMIQ increased quercetin levels and suppressed atherogenesis in this mouse model of human atherosclerosis.
In a study carried out on rats with spontaneous hypertension, EMIQ at doses of 3 and 26 mg/kg/day had a significant hypotensive effect, reducing systolic blood pressure by approximately 16–21 mmHg, but did not impact diastolic blood pressure or heart rate.
Evidence strength: Modest. The human crossover trial showing improved FMD is a meaningful acute result, but involved a single acute dose and a relatively small number of participants; blood pressure, lipid, and long-term cardiovascular outcomes remain undemonstrated in humans. Animal and preclinical data are more extensive.
EMIQ has shown significant effects in improving ocular symptoms of hay fever in double-blind clinical studies. In one study, 20 subjects with hay fever due to Japanese cedar pollinosis took two capsules daily of 100 mg EMIQ or a placebo for 8 weeks during the pollen season. During the entire study period, the total ocular score and ocular itching score for the EMIQ group were significantly lower than for the placebo group.
In another study of hay fever due to Japanese cedar pollinosis, 24 subjects took 100 mg EMIQ or a placebo for 8 weeks, starting 4 weeks prior to the onset of pollen release. During the entire study period, ocular symptom and medication scores for the EMIQ group were significantly lower than the placebo group. When limited to the pollen release period, ocular symptom and ocular congestion scores for the EMIQ group were also significantly lower than the placebo group.
Evidence strength: Moderate for ocular allergy symptoms. Two small placebo-controlled double-blind trials conducted in Japan in subjects with Japanese cedar pollinosis consistently demonstrated reductions in ocular allergy scores. These trials were conducted in a specific population with a specific allergen and were small; generalizability to other allergenic contexts requires further study.
Administration of 275 mg/day for 12 weeks reduced total body fat, visceral fat, and subcutaneous fat in Japanese subjects. This observation formed the basis for a registered clinical trial (NCT02818699). The purpose of that study was to determine the effect and safety of long-term intake of EMIQ, a natural plant product, on body fat loss in obese and overweight individuals, assessing the effect of supplementation with EMIQ versus placebo on measures of total body fat in overweight and obese adults.
In animal models, co-treatment of heat-treated green tea extract (HTGT) and EMIQ resulted in a synergistic anti-obesity effect; the combined treatment was more effective than orlistat in reducing body weight gain and adipocyte hypertrophy induced by a high-fat diet. The co-treatment also significantly reduced total body fat mass and abdominal fat volume.
Evidence strength: Preliminary. Human data consist of one Japanese study at a specific dose (275 mg/day for 12 weeks) and an ongoing or completed U.S. RCT. Animal studies are promising but the translation to robust human clinical evidence is incomplete. No large-scale, peer-reviewed, multi-center RCT results specific to EMIQ and body composition in Western populations have been published as of the available literature.
In a randomized, double-blind, placebo-controlled trial of parallel group design, forty Japanese males who played American football (mean age: 19.8 ± 1.4 years) were assigned to receive either EMIQ in whey protein or whey protein only, six days per week over 4 months. Body composition was assessed using dual-energy X-ray absorptiometry.
The results suggested that EMIQ supplementation may optimize the effect of exercise and increase muscle hypertrophy, evidenced by a significant increase in lower limb fat-free mass and muscle mass exceeding the impact of training alone. The authors suggested the results may be related to the antioxidant properties of EMIQ, as improvement in antioxidant status was observed; other mechanisms are, however, possible and require further investigation.
Preclinical data from mice additionally showed that EMIQ, a water-soluble quercetin, has been shown to intensify muscle hypertrophy in mice.
Evidence strength: Preliminary. One small, single-center RCT in young male athletes. Findings are consistent with the animal literature but are insufficient to draw definitive conclusions regarding EMIQ's role in muscle hypertrophy in broader populations.
In vitro studies with UVA-exposed human dermal fibroblasts (HDFa) demonstrated that EMIQ had protective properties by reducing collagen damage. It modulated both the TGF-β/Smad pathway and the MMP1 pathway, contributing to collagen preservation. This protective effect was further confirmed using the T-Skin™ model, a reconstructed full-thickness human skin model, which illustrated that EMIQ could defend the physiological structures of both the epidermis and dermis against UV radiation.
A 28-day clinical trial with 30 volunteers aged 31–55 years highlighted EMIQ's effectiveness. Participants using EMIQ-containing essence displayed reduced facial trans-epidermal water loss and skin roughness, alongside improved skin elasticity.
Evidence strength: Preliminary. The clinical trial was small (n=30), short duration (28 days), and used a topical formulation; the in vitro data support mechanistic plausibility. Larger, longer-term clinical studies are required.
Animal studies conducted so far showed that EMIQ administered orally can exhibit significant systemic effects. Within the research interest were anti-allergic, cardioprotective, and chemopreventive effects, which to a large extent are connected with the antioxidant and anti-inflammatory potential of EMIQ.
Similar to isoquercitrin, AGIQ has antioxidative and tumor suppressive properties in experimental animals. Research in rat models demonstrated that EMIQ supplementation can reduce oxidative stress-mediated hepatocellular tumor promotion.
Evidence strength: Preclinical only. All chemopreventive findings are currently based on animal and cell-line studies. No controlled human clinical evidence exists for cancer-related endpoints.
EMIQ is a water-soluble glycoside of quercetin produced from rutin by enzymatic treatment. Its antihypertensive effect was investigated by orally administering EMIQ to spontaneously hypertensive rats (SHR). The systolic blood pressure in SHR administered EMIQ at doses of 3 and 26 mg/kg/day was significantly lower than that in the control group on days 22, 36, and 50 of administration. The effect of EMIQ at 26 mg/kg/day was higher than equimolar administration of quercetin, though diltiazem administered as a positive control showed a stronger effect than EMIQ.
Evidence strength: Animal data only. The endothelial function human study (above) did not show significant changes in blood pressure. Direct antihypertensive effects in humans have not been established.
Conducted animal research demonstrates that EMIQ is a safe product with cardioprotective, anti-allergic, chemopreventive, neuroprotective, and musculotropic properties. Based on the totality of available research, AGIQ/EMIQ is associated with the following body systems:
The following dosages have been used or reported in specific studies and should be understood only as the doses tested in those contexts:
Alpha-glycosyl isoquercitrin (AGIQ) is marketed in Japan as a food additive and is generally recognized as safe (GRAS) by the expert panel of FEMA in 2005 and the U.S. Food and Drug Administration (FDA) in 2007.
In a 90-day rat safety study, the safety and toxicokinetics of AGIQ were tested in 60 male and 60 female Sprague-Dawley rats at dietary doses up to 5%. All animals survived until scheduled euthanasia with no clinical signs of toxicity in any animal. AGIQ was rapidly absorbed with metabolism to quercetin and quercetin glucuronide at all dose levels.
Oral administration of AGIQ in reconstituted milk supplement to preweaning Göttingen minipigs for 4 weeks at up to 1000 mg/kg/day did not result in any adverse treatment-related effects, further supporting the safety of AGIQ as a food additive.
Alpha-glycosyl isoquercitrin (AGIQ) was granted GRAS status in 2005 (FEMA) and 2007 (FDA). However, safety and toxicity information for AGIQ is sparse, and therefore the carcinogenicity potential of AGIQ was examined in the CByB6F1-Tg(HRAS)2Jic (rasH2) model. One hundred female and male rasH2 mice, each, were allocated to one of four designated dose groups: 0%, 1.5%, 3.0%, or 5.0% AGIQ; animals were administered the diets for six months.
A separate chronic rat carcinogenicity study yielded a notable finding: in the carcinogenicity study, a statistically significant increase in the incidence of malignant glioma of the brain or spinal cord was observed in female rats exposed to 5.0% AGIQ compared to those exposed to control feed. The rat carcinogenicity study identified a microglial brain tumor response; however, a Scientific Advisory Panel concluded that the microglial tumors are rat-specific.
To support expanded global marketing of food products containing AGIQ, comprehensive testing of genotoxic potential of AGIQ and isoquercitrin was conducted according to current regulatory test guidelines. Both chemicals tested positive in bacterial reverse mutation assays, and exposure to isoquercitrin resulted in chromosomal aberrations in CHO-WBL cells. However, although isoquercitrin tested positive in the chromosomal aberration assay in CHO cells, results of all other in vitro and in vivo studies assessing numerical or structural chromosomal damage or DNA damage were negative for both chemicals.
The Local Lymph Node Assay (LLNA) was used to assess AGIQ's potential to cause skin sensitization. Results indicate that no excessive irritation was observed after the irritation screen when AGIQ was tested at 5%, 10%, and 25% in DMF. AGIQ was further evaluated at 10%, 25%, and 50% in DMF in the main test, resulting in stimulation indices of less than the positive threshold of 1.6 (values of 1.2, 1.4, and 1.2, respectively). This indicates that AGIQ does not have skin sensitization hazard potential.
Previous rat toxicity studies of AGIQ, a water-soluble flavonol glycoside derived from rutin, revealed systemic yellow bone discoloration. Investigative studies were conducted to determine the AGIQ metabolite(s) responsible for the discoloration. Collectively, data implicate quercetin, quercetin 3-O-glucuronide, or 3-O-methylquercetin (or a combination thereof) as the most likely metabolite of AGIQ causing the yellow discoloration of bone in rats administered dietary AGIQ. This finding is a rat-specific effect related to metabolite accumulation and has not been demonstrated as clinically relevant in humans.
In an embryo-fetal developmental toxicity study in New Zealand White rabbits at doses of 0, 250, 500, or 1000 mg/kg/day, there was no evidence of maternal or fetal toxicity except for equivocal findings of unilateral absent kidney and ureter in one and two unrelated fetuses at 500 and 1000 mg/kg/day, respectively. These findings were regarded as equivocal and unrelated by the study investigators.
The acceptable daily intake of (95%) isoquercitrin and of EMIQ was estimated to be 5.4 and 4.9 mg/kg/day, respectively. Adverse effects of higher doses in rats included mostly (benign) chromaturia; nevertheless, some drug interactions may occur due to the modulation of the activity and/or expression of drug metabolizing/transporting systems.
No specific drug interactions have been documented for EMIQ, although theoretically, drugs metabolized by CYP3A4 and/or P-glycoprotein (Pgp) could have altered pharmacokinetics/bioavailability.
Health conditions that Alpha-glycosyl isoquercitrin may help support.
The same Japanese cedar pollinosis RCTs that examined AGIQ in seasonal allergy involved respiratory allergy subjects, though significant improvement was observed for ocular but not nasal symptom endpoints. Mechanistically, AGIQ's mast cell-stabilizing and antihistamine properties via its quercetin metabolite provide biological plausibility for respiratory allergy effects. Evidence specific to nasal/respiratory improvement is currently limited.
AGIQ is approved in Japan as an antioxidant food additive and has GRAS status from the FDA. Its enzymatic glycosylation substantially increases bioavailability of quercetin, and preclinical studies consistently show reduction of oxidative stress markers such as lipid peroxidation. Early human data from a crossover trial confirm significant elevation of plasma quercetin metabolites after acute AGIQ ingestion, supporting in vivo antioxidant activity.
The British Journal of Nutrition RCT (2019, n=25) found acute AGIQ ingestion significantly improved endothelial function in adults at cardiovascular risk, consistent with protection of arterial wall function. No significant improvements in arterial stiffness were observed in that single acute-dose study. Preclinical data suggest anti-atherosclerotic and vasculoprotective mechanisms.
A 4-month randomized, double-blind, placebo-controlled trial in 40 male American football athletes found that AGIQ/EMIQ added to whey protein supplementation significantly affected body composition and oxidative stress markers compared to whey protein alone. Preclinical studies showed AGIQ intensifies muscle hypertrophy in mice. This is direct human RCT evidence in an athletic population.
Isoquercitrin (the direct precursor and metabolite of AGIQ) belongs to a quercetin-class of flavonoids with documented antiplatelet properties in vitro and in animal models. Anti-anaphylactic cardiovascular studies show isoquercitrin blunts hemodynamic instability associated with massive mediator release. Quercetin inhibits arachidonic acid-mediated platelet aggregation. Human RCT evidence specific to AGIQ for thrombosis prevention is absent.
Isoquercitrin and its parent compound quercetin have documented hypotensive effects in animal models and are listed among AGIQ's established biological activities. However, the only human RCT of AGIQ (British Journal of Nutrition, 2019) found no significant change in blood pressure after acute AGIQ administration, even as endothelial function improved. Evidence for blood pressure lowering by AGIQ specifically in humans is currently negative or inconclusive.
Isoquercitrin (the direct metabolic precursor of AGIQ) has been shown in a clinical study to promote pancreatic islet function, improve glucose tolerance, and help regulate blood glucose levels. Quercetin, AGIQ's ultimate metabolite, has documented anti-diabetic mechanisms including alpha-glucosidase inhibition and insulin sensitization.
Isoquercitrin (the direct precursor of AGIQ) is listed among flavonoids with hypolipidemic effects, including improvement in cholesterol and triglyceride levels, in published clinical and preclinical literature. A one-month clinical study of isoquercetin demonstrated improvements in cholesterol and triglyceride levels. AGIQ, which yields isoquercitrin and quercetin in vivo, shares this mechanistic basis.
AGIQ suppresses pro-inflammatory mediators including TNF-α, IL-1β, IL-6, and nitric oxide primarily via inhibition of the NF-κB signaling pathway, demonstrated in cell and animal studies. Human-specific clinical evidence for AGIQ on inflammation remains limited, though its metabolite quercetin has some clinical anti-inflammatory data. The mechanistic and preclinical basis is robust.
A randomized, controlled, crossover trial in 25 adults at cardiovascular risk found that acute AGIQ ingestion significantly improved endothelial function (likely via flow-mediated dilation) compared to placebo, with no significant change in blood pressure or arterial stiffness. This constitutes the most direct human evidence for a circulatory benefit of AGIQ.
A 2024 mouse model study (Life Sciences) found that 4-week AGIQ administration alleviated stress-induced depressive behaviors via modulation of the microbiota-gut-brain axis, increasing 5-HT (serotonin) levels and maintaining gut barrier integrity. This is the first published evidence of AGIQ-specific antidepressant effects; all current evidence is preclinical.
AGIQ's parent compound isoquercitrin shows anti-anaphylactic cardiovascular effects in animal models, blunting both hypertensive and hypotensive anaphylactic responses and reducing death rate. Its mast cell-stabilizing and antihistamine properties, well-documented for quercetin, underlie this activity. Human evidence for AGIQ specifically in food allergy or anaphylaxis prevention is not yet established.
Two double-blind, placebo-controlled RCTs of 100 mg AGIQ/day for 8 weeks in Japanese cedar pollinosis subjects demonstrated significant improvement in ocular comfort and eye-related quality of life scores versus placebo. Flavonoids including quercetin also demonstrate mast cell-stabilizing effects in conjunctival tissue relevant to allergic eye disease.
Animal studies in rats, mice, and minipigs show AGIQ selectively increases butyrate-producing commensal bacteria (particularly Kineothrix alysoides) and genus Akkermansia without broadly disrupting gut microbiome diversity. These microbiome changes are mechanistically linked to AGIQ's downstream effects on brain function and depression. Evidence is currently preclinical.
AGIQ's comprehensive antioxidant, anti-inflammatory, hepatoprotective, and neuroprotective properties—as metabolized to quercetin in vivo—collectively align with mechanisms relevant to healthy aging. Its FDA GRAS status and long use as a food additive in Japan since 1987 support safety for long-term use. Human evidence for aging-specific outcomes is indirect.
AGIQ is characterized across multiple published reviews as possessing cardioprotective properties, including anti-anaphylactic cardiovascular effects (isoquercitrin, animal data), improved endothelial function (human RCT), and antioxidant protection of cardiac tissue. Direct human clinical trial evidence for AGIQ on specific cardiac outcomes (e.g., arrhythmia, heart failure) is not yet established.
Isoquercitrin (AGIQ's direct metabolic precursor) has demonstrated hepatoprotective and antioxidant effects in liver cell models via AMPK/YAP signaling, reducing ROS and protecting hepatocytes from oxidative damage. Animal studies show AGIQ suppresses hepatic preneoplastic lesion development. Preclinical hepatocellular health benefits of AGIQ have been noted in multiple animal experiments.
A 2023 study in the Journal of Agricultural and Food Chemistry found that 4-week AGIQ treatment in mice significantly improved learning and memory function, linked to Akkermansia enrichment in the gut, increased serum and hippocampal taurine, and upregulation of hippocampal antioxidant defense enzymes. Evidence is preclinical only.
AGIQ/EMIQ was shown to intensify muscle hypertrophy in mice, and quercetin (its metabolite) promotes recovery from post-exercise muscle inflammation in animal models. The 4-month athlete RCT (JISSN 2019) measured exercise-related oxidative stress markers as secondary outcomes. Mechanistically, reduction of exercise-induced ROS by AGIQ may support muscle repair.
Two parallel-design, double-blind, placebo-controlled trials administered 100 mg AGIQ/day for 8 weeks to subjects with Japanese cedar pollinosis (hay fever). Both studies reported significant improvement in ocular allergy symptoms (eye comfort, quality of life scores), with nasal airflow unchanged. The proposed mechanism involves mast cell stabilization and inhibition of IgE-mediated histamine release.
Body systems that Alpha-glycosyl isoquercitrin may help support.
Go back